Transmedics Group Inc
NASDAQ:TMDX

Watchlist Manager
Transmedics Group Inc Logo
Transmedics Group Inc
NASDAQ:TMDX
Watchlist
Price: 82 USD 1.72%
Market Cap: 2.8B USD
Have any thoughts about
Transmedics Group Inc?
Write Note

Transmedics Group Inc
Non-Reccuring Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Transmedics Group Inc
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
Transmedics Group Inc
NASDAQ:TMDX
Non-Reccuring Items
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Non-Reccuring Items
-$465m
CAGR 3-Years
-22%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Non-Reccuring Items
-$167m
CAGR 3-Years
34%
CAGR 5-Years
-5%
CAGR 10-Years
13%
Stryker Corp
NYSE:SYK
Non-Reccuring Items
-$466m
CAGR 3-Years
23%
CAGR 5-Years
11%
CAGR 10-Years
8%
Abbott Laboratories
NYSE:ABT
Non-Reccuring Items
-$252m
CAGR 3-Years
-24%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Intuitive Surgical Inc
NASDAQ:ISRG
Non-Reccuring Items
-$4.2m
CAGR 3-Years
27%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Transmedics Group Inc
Glance View

Market Cap
2.8B USD
Industry
Health Care

TransMedics Group, Inc. operates as a commercial stage medical technology company. The company is headquartered in Andover, Massachusetts and currently employs 148 full-time employees. The company went IPO on 2019-05-02. The company is focused on developing organ transplant therapy for end-stage organ failure patients across multiple disease states. The firm has designed and developed organ care system (OCS) a portable organ perfusion, optimization and monitoring system that utilizes customized technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed three OCS products, one for each of lung, heart and liver transplantations. Its OCS clinical programs include OCS Heart EXPAND Trial, OCS Heart EXPAND Continued Access Protocol, or CAP, Trial and OCS Heart PROCEED II Trials. Its organ care system (OCS) technology platform to perfuse donor organs with warm, oxygenated, nutrient-enriched blood, while maintaining the organs in a living, functioning state; the lung is breathing, the heart is beating and the liver is producing bile.

TMDX Intrinsic Value
46.31 USD
Overvaluation 44%
Intrinsic Value
Price

See Also

What is Transmedics Group Inc's Non-Reccuring Items?
Non-Reccuring Items
0 USD

Based on the financial report for Sep 30, 2024, Transmedics Group Inc's Non-Reccuring Items amounts to 0 USD.

Back to Top